Company Overview and News
When a role is reprised by a new actor, comparisons are almost always inevitable. However, Angel Locsin isn’t putting up with comments that put down actors, particularly Liza Soberano, who is preparing to be the new Darna.
The Duterte administration is “taking all diplomatic action” in dealing with the reported harassment of Filipino fishermen by Chinese Coast Guard personnel at Panatag Shoal, according to Foreign Secretary Alan Peter Cayetano.
GMA7 NG NGGTF NGG GNWKY
A snapshot of Gutierrez and Lamasan appeared online through the Instagram account of celebrity handler Love Capulong. She posted the image on Tuesday with the caption, “Pitching for a new project with Star Cinema With the one and only Inang!”
The outspoken GMA headwriter Suzette Doctolero, whose oeuvre includes “Encantadia” “Amaya” and “Indio,” has taken to her Facebook once again. Although Doctolero has had a few run-ins with Kapamilya comedian Ogie Diaz as well as ABS-CBN fantaserye “Bagani” in the past, this time Doctolero addressed concerns regarding GMA Network’s latest sci-fi thriller “The Cure.”
Mr. Felipe L. Gozon, the company’s chairman and chief executive officer (CEO), told reporters on the sidelines of the annual stockholders’ meeting held in Quezon City that the device will convert analog signal into digital so that more than one channel may be viewed in one frequency.
GMA Network Inc. is closing the door, for now, to potential investors as it launches new initiatives, including the nationwide rollout of its digital television platform, its Chairman and CEO Felipe Gozon said on Wednesday.
GMA7 SMCP1 GTMEY GLOPP SMGBY SMGBF GLO SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E GTMEF GLOPA GNWKY
Things are on the right track for Sunshine Cruz this year. After ending her stint at ABS-CBN’s drama series “Wildflower” earlier this year, Cruz is now embarking on her next project: another drama series called “Karibal Ko Ang Aking Ina”, but with GMA Network.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...